RSS Feed Print
Clinical Trials 2019
Lane Simonian
Posted: Monday, May 20, 2019 9:57 AM
Joined: 12/12/2011
Posts: 4589


Michael Ellenbogen kindly sent me a report detailing ongoing drug clinical trials for Alzheimer's disease.  Here are parts of the summary:

New BIO Report: More Progress Needed in Innovation of Alzheimer’s Disease Therapeutics

Poor R&D Success Rates: Clinical development success for disease-modifying drug programs for Alzheimer’s has been difficult in late-stage trials, with no disease-modifying drugs moving beyond Phase III to FDA filing. Since 2008, a total of 87 clinical-stage disease-modifying programs have been suspended.

  • Growing & Diverse R&D Pipeline: There are 74 clinical-stage programs with disease-modifying potential in Alzheimer’s disease. The drug candidates in these programs are attempting to stop, prevent, or slow the progression of Alzheimer’s disease using 10 different strategies involving 30 distinct molecular targets. Small biotech companies account for more than three-fourths of these clinical programs.
The three main targets currently are amyloid, tau, and neuroinflammation.  By contrast there is only one pharmaceutical sponsored trial targeting oxidation.

Lane Simonian
Posted: Tuesday, May 21, 2019 10:21 AM
Joined: 12/12/2011
Posts: 4589


Here is a list of the ten strategies for treating Alzheimer's disease and the number of clinical trials for each:

Targeting the Amyloid Pathway (33)

Targeting the Tau Pathway (12)

Regeneration of Neurons (12)

Reversing Neuroinflammation (7)

Targeting Epigenetic Modification (3)

Targeting Metabolic Pathways (2)

Targeting Glucocorticoids (2)

Targeting Oxidative Stress (1)

Targeting Infectious Agents (1)

Targeting the Epichaperon (1)

Here is some information on preclinical trials:

Preclinical Pipeline To predict what may enter the clinical pipeline soon, we examined novel preclinical disease-modifying Alzheimer’s disease programs in the Biomedtracker databases and recently published literature. We found that 23 of the 102 preclinical programs listed had unique targets not currently in the clinic, indicating further advances may be on the horizon. The mechanistic strategies are quite varied within the 23 new targets, including caspases, different growth receptors, inflammation factors, kinases, and modified blood proteins that may restore or protect neuronal function. Sixteen of the preclinical programs had unknown mechanisms



HowDoYouDeal
Posted: Friday, May 31, 2019 9:04 AM
Joined: 2/17/2019
Posts: 220


You may want to have a look at non-drug therapies.

  Montpelier France, and YANKEE EYE CLINIC, EAGAN, MINNESOTA

Row Saved Status Study Title Conditions Interventions Locations 1
Recruiting REGEnLIFE RGn530 - Feasibility Pilot
  • Alzheimer Disease
  • Device: Photobiomodulation REGEnLIFE RGn530 device
  • Device: SHAM REGEnLIFE RGn530 device
  • Montpellier University Hospital, Gui de Chauliac
    Montpellier, France
2
Recruiting Photobiomodulation & Ketogenic Diet for Treatment of Mid-periphery Retinal Disorders for Alzheimer's Disease Prevention
  • Diabetic Retinopathy (DR)
  • Age-related Macular Degeneration (AMD)
  • Mid-peripheral Drusen Formation
  • Diabetic Macular Edema (DME)
  • Behavioral: Photobiomodulation
  • Behavioral: Ketogenic diet
  • Yankee Eye Clinic
    Eagan, Minnesota, United States

 



HowDoYouDeal
Posted: Tuesday, June 11, 2019 11:12 AM
Joined: 2/17/2019
Posts: 220


Vie Light announced a clinical trial on June 6, 2019

 

here are the results from the first trial, which had five people:

 


Lane Simonian
Posted: Wednesday, July 10, 2019 3:39 PM
Joined: 12/12/2011
Posts: 4589


Another source of information on clinical trials for Alzheimer's disease in 2019.

https://www.sciencedirect.com/science/article/pii/S2352873719300290


HowDoYouDeal
Posted: Sunday, July 21, 2019 12:46 PM
Joined: 2/17/2019
Posts: 220


There are 2150 clinical trials worldwide for Alzheimers.  Use www.clinicaltrials.gov

 

 Check here for Clinical trials in your area

https://clinicaltrials.gov/ct2/results?cond=Alzheimer+Disease&term=&cntry=&state=&city=&dist=

 

CLINICALTRIALS.GOV

 

 

 


HowDoYouDeal
Posted: Sunday, July 21, 2019 12:59 PM
Joined: 2/17/2019
Posts: 220


23 light therapy studies for Alzheimers are currently recruiting

 

 64 (SIXTY-FOUR) Studies for LIGHT THERAPY ALZHEIMER DISEASE

 https://clinicaltrials.gov/ct2/results?cond=Alzheimer+Disease&term=light+therapy&cntry=&state=&city=&dist=&Search=Search

 

64 Studies found for: light therapy | Alzheimer Disease
Also searched for Disorders, Treatment, Light and more. See Search Details
Filters
Status
Open or close this filter
Recruitment :
  • Not yet recruiting
  • Recruiting
  • Enrolling by invitation
  • Active, not recruiting
  • Suspended
  • Terminated
  • Completed
  • Withdrawn
  • Unknown status†
Open or close the Expanded Access FiltersExpanded Access :
Eligibility Criteria
Open or close this filter
Age :
yearsORAge Group :
Child (birth–17)
Adult (18–64)
Older Adult (65+)

Sex :
All
Female
Male
Accepts Healthy Volunteers
Study Type
Open or close this filter
Study Results
Open or close this filter
Study Phase
Open or close this filter
Funder Type
Open or close this filter
Study Documents
Open or close this filter
studies per page
Row Saved Status Study Title Conditions Interventions Locations 1
Completed Effects of Light-therapy in Alzheimer's Disease
  • Alzheimer's Disease
  • Other: Luxtherapy
  • Hôpital Charles Foix
    Ivry-sur-Seine, France
2
Completed High Intensity Light Therapy in Alzheimer's Disease
  • Alzheimer's Disease
  • Dementia
  • Device: high-intensity light therapy
  • John Umstead Hospital
    Butner, North Carolina, United States
3
Completed Effect of Therapeutic Light on Sleep, Circadian Rhythm, and Global Function in Women With Alzheimer's
  • Alzheimer's Disease
  • Device: Morning Simulated Sunlight
  • Device: Non-therapeutic Red Light
  • Botsford Continuing Care
    Farmington Hills, Michigan, United States
4
Recruiting Light and the Effect on Metabolic Syndrome and Alzheimer's Disease
  • Alzheimer Disease
  • Diabetes Mellitus, Type 2
  • Device: Tailored Lighting Intervention
  • Rensselaer Polytechnic Institute
    Troy, New York, United States
5
Completed Deep Brain Stimulation (DBS) of the Nucleus Basalis Meynert (NBM) to Treat Cognitive Deficits in Light to Moderate Alzheimer's Disease
  • Alzheimer Disease
  • Other: Deep brain stimulation
  • Uni-Klinik Köln AöR
    Cologne, North Rhine Westphalia, Germany
6
Recruiting Alzheimer's Disease Treatment With Combination of 40Hz Light and Cognitive Therapy
  • Alzheimer Disease
  • Mild Cognitive Impairment
  • Dementia
  • (and 3 more...)
  • Device: Combination of 40Hz light and cognitive therapy (ALZLIFE)
  • Andrey Vyshedskiy
    Miami, Florida, United States
7
Recruiting Light, Metabolic Syndrome and Alzheimer's Disease
  • Mild Cognitive Impairment
  • Alzheimer Disease
  • Type2 Diabetes
  • Device: Tailored Lighting Intervention
  • Mount Sinai School of Medicine
    New York, New York, United States
8
Not yet recruiting An Evaluation of Low Level Laser Light Therapy on Improving the Symptoms of Alzheimer's Disease
  • Alzheimer's Disease
  • Device: Erchonia ALS Laser
  • Device: Placebo Laser
  • Pruebas Clinicas
    Zapopan, Jalisco, Mexico
  • Neocemod
    La Plazuela, Pocitos AGS, Mexico
9
Completed
Has Results Light Treatment for Sleep/Wake Disturbances in Alzheimer's Disease
  • Sleep Initiation and Maintenance Disorders
  • Device: Bright light
  • Device: Control
  • VA Palo Alto Health Care System
    Palo Alto, California, United States
10
Recruiting Impact of Photobiomodulation (PBM) on Biomarkers of Alzheimer's Disease
  • Alzheimer Disease
  • Device: Vielight Neuro Gamma
  • Other: Sham Vielight Neuro Gamma
  • VA Health Care System
    San Francisco, California, United States
  • UCSF Memory and Aging Center
    San Francisco, California, United States
Showing: 1-10 of 64 studies    
Study has passed its completion date and status has not been verified in more than two years.

HowDoYouDeal
Posted: Saturday, August 17, 2019 12:19 PM
Joined: 2/17/2019
Posts: 220


Nice! Thank-you. I love the graphs.

postmortum
Posted: Thursday, August 22, 2019 11:21 AM
Joined: 8/15/2019
Posts: 1


postmortum Question 1: A diagnosis of AD during life could only be “probable”, whereas a “definite” diagnosis required post-mortem histopathological confirmation. 

Question: Is this not confusing for the patient and his/her caregiver? Them why continue using The Diagnosis Alzheimer''s Disease??? 


Question 2:  The terminologies Dementia and Alzheimer''s used interchangeable also by doctors? Is this not Confusing???  Confusing for the patients, readers of research articles???

Question 3: from Latin term DEMENTIA means: ‘out of one''s mind’, Crazy, "madness, distraction, folly," . Why is this term still used to label people with memory disorders/problems??? 
Since Major neurocognitive disorder of the DSM-5 replaces the DSM-IV''s term ''DEMENTIA" or other debilitating Cognitive conditions'' Why not stick to The DSM-5 distinctions between ''mild'' and ''major'' neurocognitive disorders? and in doing so to eliminate all the confusions especially for the patients and their caregivers? 
For Research Purpose this will be beneficial for the uniformity...Standardization???? Alzheimer''s is not the sole Neurocognitive Disorder....Food for thought!  Or am I wrong??? 

BobReny
Posted: Wednesday, September 4, 2019 4:22 AM
Joined: 6/15/2019
Posts: 5


Specialists from Temple University discovered that there is a connection between the movement of Alzheimer's and some useless changes in calcium transport by the cell's mitochondria, which contains chemicals in charge of creating vitality.

Now researcher are working on remodeling of calcium transport by mitochondria

https://www.myhealthyclick.com/temple-university-researchers-discover-new-cellular-target-to-treat-alzheimers/


HowDoYouDeal
Posted: Monday, September 9, 2019 10:12 PM
Joined: 2/17/2019
Posts: 220


Thank you Bob. Its about time the media started to publish information about this juggernaut of a breakthrough.

When Alois Alzheimer defined the disease, he warned the medical community, do not be tempted to think that amyloid plaques and neurofibrillary (tau) tangles are the cause of this disease, they are but symptoms.

Since its discovery in1906,  it only took us 113 years to find out he was right.